Telos Capital Management Inc. Has $12.44 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Posted by Defense World Staff on Oct 9th, 2023

Telos Capital Management Inc. decreased its holdings in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 0.1% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 75,173 shares of the company’s stock after selling 103 shares during the quarter. Johnson & Johnson makes up 1.7% of Telos Capital Management Inc.’s holdings, making the stock its 14th biggest position. Telos Capital Management Inc.’s holdings in Johnson & Johnson were worth $12,443,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in JNJ. Moneta Group Investment Advisors LLC increased its position in Johnson & Johnson by 90,144.4% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 54,386,720 shares of the company’s stock worth $9,607,414,000 after buying an additional 54,326,454 shares during the period. Norges Bank bought a new position in Johnson & Johnson during the 4th quarter worth $4,609,399,000. Providence Capital Advisors LLC increased its position in Johnson & Johnson by 141,974.0% during the 1st quarter. Providence Capital Advisors LLC now owns 4,750,956 shares of the company’s stock worth $30,651,000 after buying an additional 4,747,612 shares during the period. Morgan Stanley increased its position in Johnson & Johnson by 12.0% during the 4th quarter. Morgan Stanley now owns 42,224,521 shares of the company’s stock worth $7,458,962,000 after buying an additional 4,521,062 shares during the period. Finally, Price T Rowe Associates Inc. MD increased its position in shares of Johnson & Johnson by 15.1% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 29,277,774 shares of the company’s stock worth $5,171,919,000 after purchasing an additional 3,849,148 shares during the period. Institutional investors own 68.40% of the company’s stock.

Johnson & Johnson Price Performance

JNJ stock opened at $157.64 on Monday. The company has a fifty day moving average price of $164.30 and a 200-day moving average price of $162.40. The company has a market capitalization of $409.70 billion, a P/E ratio of 31.91, a PEG ratio of 3.19 and a beta of 0.55. Johnson & Johnson has a 52-week low of $150.11 and a 52-week high of $181.04. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.88 and a current ratio of 1.12.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last released its quarterly earnings results on Thursday, July 20th. The company reported $2.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.62 by $0.18. The firm had revenue of $25.53 billion during the quarter, compared to the consensus estimate of $24.63 billion. Johnson & Johnson had a net margin of 13.35% and a return on equity of 36.72%. The company’s revenue for the quarter was up 6.3% on a year-over-year basis. During the same quarter last year, the firm earned $2.59 earnings per share. As a group, equities analysts expect that Johnson & Johnson will post 10.02 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, September 7th. Stockholders of record on Monday, August 28th were paid a dividend of $1.19 per share. This represents a $4.76 annualized dividend and a dividend yield of 3.02%. The ex-dividend date of this dividend was Friday, August 25th. Johnson & Johnson’s payout ratio is currently 96.36%.

Analysts Set New Price Targets

A number of research analysts recently commented on the company. Wells Fargo & Company decreased their price target on Johnson & Johnson from $195.00 to $186.00 and set an “overweight” rating on the stock in a research report on Thursday, August 31st. Stifel Nicolaus raised their price target on Johnson & Johnson from $165.00 to $175.00 in a research report on Friday, July 21st. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Friday, September 29th. Raymond James decreased their price target on Johnson & Johnson from $184.00 to $179.00 and set an “outperform” rating on the stock in a research report on Tuesday, September 5th. Finally, JPMorgan Chase & Co. raised their price target on Johnson & Johnson from $175.00 to $180.00 and gave the stock a “neutral” rating in a research report on Friday, July 21st. Nine equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $171.06.

Check Out Our Latest Analysis on JNJ

Insider Transactions at Johnson & Johnson

In other news, VP Peter Fasolo sold 20,000 shares of the stock in a transaction on Tuesday, July 25th. The shares were sold at an average price of $170.32, for a total transaction of $3,406,400.00. Following the completion of the sale, the vice president now directly owns 102,696 shares in the company, valued at $17,491,182.72. The transaction was disclosed in a filing with the SEC, which is available at this link. In other Johnson & Johnson news, VP Peter Fasolo sold 20,000 shares of the firm’s stock in a transaction on Tuesday, July 25th. The shares were sold at an average price of $170.32, for a total value of $3,406,400.00. Following the completion of the sale, the vice president now directly owns 102,696 shares in the company, valued at $17,491,182.72. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider William Hait sold 14,698 shares of the firm’s stock in a transaction on Wednesday, July 26th. The stock was sold at an average price of $172.00, for a total transaction of $2,528,056.00. Following the completion of the sale, the insider now owns 87,747 shares of the company’s stock, valued at $15,092,484. The disclosure for this sale can be found here. 0.20% of the stock is currently owned by corporate insiders.

Johnson & Johnson Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.